RecombiMAb anti-rat/mouse CD71 (TfR1)

About RecombiMAb anti-rat/mouse CD71 (TfR1)

The OX-26-CP059 monoclonal antibody is a recombinant, chimeric version of the original OX-26 antibody. The variable domain sequences are identical but the constant region sequences have been switched from mouse IgG2a, kappa to rat IgG2a, kappa for use in rat models. Species-matched chimeric antibodies exhibit regulated effector functions—including Fc receptor binding and complement activation—and result in less immunogenicity and formation of anti-drug antibodies (ADAs) than xenogenic antibodies in animal models. The highly controlled sequence and lack of genetic drift in recombinant antibodies provide more reliable and reproducible results over hybridoma derived antibodies. The OX-26 monoclonal antibody reacts with rat and mouse CD71, also known as transferrin receptor protein 1 (TfR1). CD71 is a type II homodimeric transmembrane glycoprotein which is expressed on the surface of proliferating cells, reticulocytes, and erythroid precursors. CD71 plays a role in the control of cellular proliferation and is required for iron import from transferrin into cells by endocytosis. CD71 is overexpressed on many different types of cancer cells and expression level correlates with advanced stage and/or poorer prognosis in several cancers, including solid cancers. Elevated levels of CD71 expression on malignant cells, together with its extracellular accessibility, ability to internalize, and central role in cancer cell pathology make this receptor an attractive target for antibody-mediated therapy. The anti-tumor and cytotoxic activities of anti-TfR1 antibodies have been demonstrated to require Fc effector function to elicit antibody-dependent cell-mediated cytotoxicity and antibody-dependent cell-mediated phagocytosis. In addition, cells of the vascular endothelium of brain capillaries that compose the blood-brain barrier (BBB) also express high levels of CD71 allowing for receptor-mediated transcytosis of large biomolecules into the brain. OX-26 has been used as a BBB transporter in rats and mice and is suitable for studying CD71 expression and iron uptake into different tissues. The OX-26 antibody is often used to transport conjugated drugs across the BBB in experimental models.